{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:53Z","timestamp":1787003633710,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29686-9","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T07:34:57Z","timestamp":1764228897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults"],"prefix":"10.1038","volume":"15","author":[{"given":"Sant","family":"Muangnoicharoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranath","family":"Lawpoolsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthaporn","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viravarn","family":"Luvira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Jongkaewwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sira","family":"Nanthapisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapong","family":"Phumratanaprapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supitcha","family":"Kamolratanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumon","family":"Thanthamnu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatnapa","family":"Duangdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punnee","family":"Pitisuttithum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"29686_CR1","doi-asserted-by":"crossref","unstructured":"Sheikh, A., Robertson, C. & Taylor, B. BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant. N Engl. J. Med 385, (2021).","DOI":"10.1056\/NEJMc2113864"},{"key":"29686_CR2","doi-asserted-by":"crossref","unstructured":"Sritipsukho, P. et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect 11, (2022).","DOI":"10.1080\/22221751.2022.2037398"},{"key":"29686_CR3","doi-asserted-by":"crossref","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis 22, (2022).","DOI":"10.1016\/S1473-3099(22)00320-6"},{"key":"29686_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and coronavac against COVID-19 in Hong kong: a population-based observational study. Lancet Infect. Dis. 22, 1435\u20131443 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"29686_CR5","doi-asserted-by":"crossref","unstructured":"Kudlay, D., Svistunov, A. & Satyshev, O. COVID-19 vaccines: an updated overview of different platforms. Bioeng 9, (2022).","DOI":"10.3390\/bioengineering9110714"},{"key":"29686_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.010","author":"S Muangnoicharoen","year":"2024","unstructured":"Muangnoicharoen, S. et al. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1\/2 open-label trial. Vaccine https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.010 (2024).","journal-title":"Vaccine"},{"key":"29686_CR7","doi-asserted-by":"crossref","unstructured":"Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health 10, (2022).","DOI":"10.1016\/S2214-109X(22)00112-7"},{"key":"29686_CR8","unstructured":"Infectious Diseases Society of America. COVID-19 variant update. https:\/\/www.idsociety.org\/covid-19-real-time-learning-network\/diagnostics\/covid-19-variant-update\/"},{"key":"29686_CR9","unstructured":"European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 30 August 2024. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern"},{"key":"29686_CR10","unstructured":"American Medical Association. Genetic variants of SARS-CoV-2\u2014What do they mean? https:\/\/jamanetwork.com\/"},{"key":"29686_CR11","unstructured":"World Health Organization. Thailand country profile. https:\/\/www.who.int\/countries\/tha"},{"key":"29686_CR12","unstructured":"World Health Organization. Weekly epidemiological update on COVID-19\u201329 June (2022). https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---29-june-2022"},{"key":"29686_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat. Microbiol. 7, 423\u2013433 (2022).","journal-title":"Nat. Microbiol."},{"key":"29686_CR14","doi-asserted-by":"crossref","unstructured":"Moriyama, S. et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to Circulating SARS-CoV-2 variants. Immunity 54, (2021).","DOI":"10.1016\/j.immuni.2021.06.015"},{"key":"29686_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1056\/NEJMc2214916","volume":"388","author":"J Zou","year":"2023","unstructured":"Zou, J. et al. Neutralization of BA.4\u2013BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl. J. Med. 388, 854\u2013857 (2023).","journal-title":"N Engl. J. Med."},{"key":"29686_CR16","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 Circulating variants. Nat Commun 14, (2023).","DOI":"10.1038\/s41467-023-37926-7"},{"key":"29686_CR17","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","volume":"57","author":"MA Tortorici","year":"2024","unstructured":"Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904\u2013911e4 (2024).","journal-title":"Immunity"},{"key":"29686_CR18","doi-asserted-by":"crossref","unstructured":"Horndler, L. et al. Decreased breadth of the antibody response to the Spike protein of SARS-CoV-2 after repeated vaccination. Front Immunol 14, (2023).","DOI":"10.3389\/fimmu.2023.1157263"},{"key":"29686_CR19","doi-asserted-by":"crossref","unstructured":"Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol 8, (2023).","DOI":"10.1126\/sciimmunol.ade2798"},{"key":"29686_CR20","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S1473-3099(24)00134-8","volume":"24","author":"K Kocher","year":"2024","unstructured":"Kocher, K. et al. Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual. Lancet Infect. Dis. 24, e272\u2013e274 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"29686_CR21","doi-asserted-by":"crossref","unstructured":"Suthar, M. S. et al. Durability of immune responses to the BNT162b2 mRNA vaccine. Med.\u00a0 3, (2022).","DOI":"10.1101\/2021.09.30.462488"},{"key":"29686_CR22","doi-asserted-by":"crossref","unstructured":"Kim, D. I. et al. Immunogenicity and durability of antibody responses to homologous and heterologous vaccinations with BNT162b2 and ChAdOx1 vaccines for COVID-19. Vaccines (Basel) 10, (2022).","DOI":"10.3390\/vaccines10111864"},{"key":"29686_CR23","doi-asserted-by":"crossref","unstructured":"Hyun, H. J. et al. Neutralizing activity against BQ.1.1, BN.1, and XBB.1 in bivalent COVID-19 vaccine recipients: comparison by the types of prior infection and vaccine formulations. Vaccines (Basel) 11, (2023).","DOI":"10.3390\/vaccines11081320"},{"key":"29686_CR24","doi-asserted-by":"crossref","unstructured":"Collier, A. Y. et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl. J. Med 388, (2023).","DOI":"10.1101\/2022.10.24.513619"},{"key":"29686_CR25","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1056\/NEJMc2302462","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin, D. Y. et al. Durability of bivalent boosters against Omicron subvariants. N Engl. J. Med. 388, 1818\u20131820 (2023).","journal-title":"N Engl. J. Med."},{"key":"29686_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/vaccines12091014","volume":"12","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. Assessing the impact of primary-series infection and booster vaccination on protection against Omicron in Hong kong: a population-based observational study. Vaccines (Basel). 12, 1014 (2024).","journal-title":"Vaccines (Basel)"},{"key":"29686_CR27","doi-asserted-by":"crossref","unstructured":"Taus, E. et al. Persistent memory despite rapid contraction of Circulating T cell responses to SARS-CoV-2 mRNA vaccination. Front Immunol 14, (2023).","DOI":"10.3389\/fimmu.2023.1100594"},{"key":"29686_CR28","doi-asserted-by":"crossref","unstructured":"Stieber, F. et al. Durability of COVID-19 vaccine induced T-cell mediated immune responses measured using the quantiferon SARS-CoV-2 assay. Pulmonology 29, (2023).","DOI":"10.1016\/j.pulmoe.2022.09.006"},{"key":"29686_CR29","doi-asserted-by":"crossref","unstructured":"Guerrera, G. et al. BNT162b2 vaccination induces durable SARS-CoV-2\u2013specific T cells with a stem cell memory phenotype. Sci Immunol 6, (2021).","DOI":"10.1126\/sciimmunol.abl5344"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29686-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:20:06Z","timestamp":1777130406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29686-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29686"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29686-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Mahidol University Institutional Research Ethics Board (MUTM 2023-028-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"45555"}}